Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.03)
# 1,266
Out of 5,165 analysts
109
Total ratings
51.52%
Success rate
8.94%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Maintains: Overweight | $6 → $10 | $6.75 | +48.15% | 2 | Feb 4, 2026 | |
| INSM Insmed | Maintains: Overweight | $216 → $230 | $144.60 | +59.06% | 1 | Dec 16, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Overweight | $4 | $1.98 | +102.02% | 1 | Dec 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $8.81 | +24.86% | 2 | Oct 30, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $0.46 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $534.30 | -1.74% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $57.43 | +56.71% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $466.10 | +2.98% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $59.71 | -7.89% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $145.21 | -44.91% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $11.14 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $756.91 | +34.10% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $366.25 | +10.58% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $318.91 | -31.02% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $14.31 | -30.12% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $2.77 | +134.66% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $48.42 | +48.70% | 1 | Apr 13, 2023 |
CytomX Therapeutics
Feb 4, 2026
Maintains: Overweight
Price Target: $6 → $10
Current: $6.75
Upside: +48.15%
Insmed
Dec 16, 2025
Maintains: Overweight
Price Target: $216 → $230
Current: $144.60
Upside: +59.06%
Inhibikase Therapeutics
Dec 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.98
Upside: +102.02%
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $8.81
Upside: +24.86%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.46
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $534.30
Upside: -1.74%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $57.43
Upside: +56.71%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $466.10
Upside: +2.98%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $59.71
Upside: -7.89%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $145.21
Upside: -44.91%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $11.14
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $756.91
Upside: +34.10%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $366.25
Upside: +10.58%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $318.91
Upside: -31.02%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $14.31
Upside: -30.12%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $2.77
Upside: +134.66%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $48.42
Upside: +48.70%